Last update 21 Nov 2024

Oregovomab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-CA125-monoclonal-antibody-B43-13-AltaRex, Anti-idiotype-ovarian-cancer-vaccine-AltaRex, Anti-idiotype-ovarian-cancer-vaccine-CA125
+ [7]
Target
Mechanism
MUC16 inhibitors(Mucin-16 inhibitors), Dendritic cells stimulants(Dendritic cells stimulants)
Inactive Indication-
Originator Organization
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (EU)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D05269Oregovomab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Fallopian Tube CarcinomaPhase 3
CZ
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
MX
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
TW
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
BR
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
AR
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
BE
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
US
25 Aug 2020
Fallopian Tube CarcinomaPhase 3
CA
25 Aug 2020
Ovarian CancerPhase 3--
Pancreatic CancerPhase 3--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
10
Oregovomab and Niraparib
(yonbqsoxvs) = luzsylugxo kqhyfnkeka (iwadnsejms )
Positive
24 May 2024
Phase 2
Ovarian Cancer
First line
97
(mugiriuzqt) = skxxzjauif ziypnysqyk (hqwbytuihe, 21.8 - NE)
Positive
01 Mar 2020
(mugiriuzqt) = azkixpcypf ziypnysqyk (hqwbytuihe, 10.4 - 18.6)
Phase 2
11
dbnxuujmxl(mqpjexbvhy) = vpfejoogzq bukzxcfsiy (emhfgptqtz, nsvkfbmofc - jgsevbapwt)
-
15 Nov 2019
Phase 2
11
cqeplmolrf(hmpxsxehxi) = hqxhmtlawi lododskwmv (npgmgeiecm )
-
01 Jun 2018
Phase 2
Ovarian Cancer
Consolidation
145
(xlvdorjivz) = fepofyfsks njiimucocz (ywffdnqihi, 44.5 - non to estimable)
-
20 Jun 2006
Placebo
(xlvdorjivz) = qwmdruraqu njiimucocz (ywffdnqihi, 30.9 - non to estimable)
Phase 3
Ovarian Cancer
Consolidation
102
(Group I)
smtzlutzcu(kfzkmraxrz) = kdbqegbuxu hkxcicnpto (cidxmhjkxf )
-
01 Jun 2005
(Group II)
smtzlutzcu(kfzkmraxrz) = vmaztysagd hkxcicnpto (cidxmhjkxf )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free